Glenmark shares surged 10% after its unit signed an exclusive licensing agreement with U.S. pharma major AbbVie.

• The deal centers on Glenmark’s novel cancer treatment, boosting investor sentiment and future growth prospects.
• Exclusive licensing with AbbVie enhances Glenmark’s global presence in oncology therapeutics.
• Stock reacts sharply to the announcement, reflecting market confidence in the partnership’s potential.